Literature DB >> 11512139

Using observational data to estimate prognosis: an example using a coronary artery disease registry.

E R DeLong1, C L Nelson, J B Wong, D B Pryor, E D Peterson, K L Lee, D B Mark, R M Califf, S G Pauker.   

Abstract

With the proliferation of clinical data registries and the rising expense of clinical trials, observational data sources are increasingly providing evidence for clinical decision making. These data are viewed as complementary to randomized clinical trials (RCT). While not as rigorous a methodological design, observational studies yield important information about effectiveness of treatment, as compared with the efficacy results of RCTs. In addition, these studies often have the advantage of providing longer-term follow-up, beyond that of clinical trials. Hence, they are useful for assessing and comparing patients' long-term prognosis under different treatment strategies. For patients with coronary artery disease, many observational comparisons have focused on medical therapy versus interventional procedures. In addition to the well-studied problem of treatment selection bias (which is not the focus of the present study), three significant methodological problems must be addressed in the analysis of these data: (i) designation of the therapeutic arms in the presence of early deaths, withdrawals, and treatment cross-overs; (ii) identification of an equitable starting point for attributing survival time; (iii) site to site variability in short-term mortality. This paper discusses these issues and suggests strategies to deal with them. A proposed methodology is developed, applied and evaluated on a large observational database that has long-term follow-up on nearly 10 000 patients. Copyright 2001 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2001        PMID: 11512139     DOI: 10.1002/sim.930

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  7 in total

Review 1.  Global registries for measuring pharmacoeconomic and quality-of-life outcomes: focus on design and data collection, analysis and interpretation.

Authors:  Lisa Kennedy; Ann-Marie Craig
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

Review 2.  Prognostic value of gated myocardial perfusion SPECT.

Authors:  Leslee J Shaw; Ami E Iskandrian
Journal:  J Nucl Cardiol       Date:  2004 Mar-Apr       Impact factor: 5.952

Review 3.  It's time to choose the study design!: net benefit analysis of alternative study designs to acquire information for evaluation of health technologies.

Authors:  Oren Shavit; Moshe Leshno; Assaf Goldberger; Amir Shmueli; Amnon Hoffman
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

4.  The risk of death associated with delayed coronary artery bypass surgery.

Authors:  Boris G Sobolev; Adrian R Levy; Lisa Kuramoto; Robert Hayden; James M Brophy; J Mark FitzGerald
Journal:  BMC Health Serv Res       Date:  2006-07-05       Impact factor: 2.655

5.  The occurrence of adverse events in relation to time after registration for coronary artery bypass surgery: a population-based observational study.

Authors:  Boris G Sobolev; Guy Fradet; Lisa Kuramoto; Basia Rogula
Journal:  J Cardiothorac Surg       Date:  2013-04-11       Impact factor: 1.637

6.  Evaluation of supply-side initiatives to improve access to coronary bypass surgery.

Authors:  Boris G Sobolev; Guy Fradet; Lisa Kuramoto; Rita Sobolyeva; Basia Rogula; Adrian R Levy
Journal:  BMC Health Serv Res       Date:  2012-09-11       Impact factor: 2.655

7.  Survival benefit of coronary-artery bypass grafting accounted for deaths in those who remained untreated.

Authors:  Boris G Sobolev; Guy Fradet; Robert Hayden; Lisa Kuramoto; Adrian R Levy; Mark J Fitzgerald
Journal:  J Cardiothorac Surg       Date:  2008-07-17       Impact factor: 1.637

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.